Onderneming Mateon Therapeutics, Inc. Other OTC
Aandelen
MATN
US57667K1097
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Biopharmaceutical
100,0
%
| 0 | nan % | 0 | 100,0 % | - |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 0 | nan % | 0 | 100,0 % | - |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Vuong Trieu
CEO | Chief Executive Officer | 59 | 22-04-19 |
Director of Finance/CFO | 57 | 01-07-19 | |
Seymour H. Fein
CTO | Chief Tech/Sci/R&D Officer | 75 | 06-01-20 |
Anthony Maida
CTO | Chief Tech/Sci/R&D Officer | 59 | 11-05-20 |
Saran Saund
PRN | Corporate Officer/Principal | 66 | 01-11-19 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Steven King
BRD | Director/Board Member | 59 | 11-05-20 |
Anthony Maida
CTO | Chief Tech/Sci/R&D Officer | 59 | 11-05-20 |
Vuong Trieu
CEO | Chief Executive Officer | 59 | 22-04-19 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 399 684 128 | 180 543 314 ( 45,17 %) | 0 | 45,17 % |
Bedrijfsgegevens
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+19,33% | 125 mld. | |
+13,95% | 109 mld. | |
-3,53% | 24,74 mld. | |
+2,71% | 22,67 mld. | |
-9,95% | 18,14 mld. | |
-41,48% | 16,67 mld. | |
-12,62% | 16,64 mld. | |
+0,99% | 13,45 mld. | |
+21,79% | 11,32 mld. |